Breast Cancer Research

Table 1 Patients included in ATM analyses

From: Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

Cohort		ATM coding region			ATM promoter
No.	Therapy	Mutations	mRNA levels	Copy no.	Mutations	Methylation	Survival
		n	n	n	n	n	n
1	Doxorubicin	70	69	69	70	-	69
	FUMI
2	Epirubicin	41	109¹	-	41	109¹	109¹
3	Paclitaxel	38	114²	-	38	-	114²

¹ Among the 109 patients, two were omitted from statistical analyses as protocol violators.
² Among the 114 patients, 8 had non-evaluable response to therapy.

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com